# New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07559760/  
OnCo record `nct07559760` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by The First Hospital of Jilin University, now recruiting.

## Summary

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07559760 by The First Hospital of Jilin University, with a registry enrolment figure of 30 participants, started 2025-11-01 and due to reach its primary completion in 2027-05-31. Interventions recorded: Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: mPFS. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07559760
- Phase: 2
- Setting: A Prospective Study of Levoleucovorin/5-FU Co-Infusion Combined With Liposomal Irinotecan ±Cetuximab/Bevacizumab as Second-Line Therapy for MSS Metastatic Colorectal Cancer
- Sponsor: The First Hospital of Jilin University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07559760: https://clinicaltrials.gov/study/NCT07559760

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07559760.json